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Abstract
Vorinostat is a histone deacetylase inhibitor used in the treatment of recurrent or persistent
cases of cutaneous T-cell lymphoma (CTCL). A retrospective review of 116 patients from phase
I and II clinical trials who had a baseline and at least one subsequent ECG revealed that four
patients had Grade 2 and one patient had Grade 3 QTc interval prolongation; however,
a MEDLINE search found no reported cases of torsades de pointes (TdP) in patients treated
with vorinostat. We describe the case of a 49 year-old male with a history of CTCL actively
undergoing treatment with vorinostat. During day 1 of hospitalization, he developed a pulseless
polymorphic ventricular tachycardia requiring resuscitation. He was found to have a QTc of
826 ms. Following correction of potassium and magnesium, QTc gradually decreased and no
further ventricular arrhythmia was noted. Other factors implicated in this case included
concurrent sertraline and doxepin therapy (both drugs have been associated with the develop-
ment of TdP in overdose). The mechanism of development of TdP in this patient is postulated
to be related to vorinostat use in combination with hypokalemia and concomitant treatment
with medications associated with QTc prolongation. This case highlights the importance of
post-market surveillance. (Cardiol J 2012; 19, 4: 434–438)
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Case report
We report the case of a 49 year-old African
American man with a history of cutaneous T-cell
lymphoma (CTCL), liver disease, renal insufficien-
cy, hemolytic anemia, and right hepatic lobe heman-
gioma who was admitted to hospital with a four-day
history of hematemesis, hematochezia, and a syn-
copal episode. Prior to admission, he was being
treated with vorinostat (Zolinza®) for CTCL and
took his last dose on the day prior to admission.
Electrocardiogram (ECG) on admission (Fig. 1)
demonstrated sinus rhythm at a rate of 79 with
a QTc interval of 826 ms and T-wave inversions
throughout the precordial and limb leads. QRS
duration was 60 ms. A comparison ECG from
48 months prior to admission (Fig. 2) demonstrat-
ed normal sinus rhythm at a rate of 62 with a QTc
interval of 400 ms. Admission laboratory tests were
notable for BUN 36 mg/dL, serum creatinine 1.7 mg/
/dL, glucose 174 mg/dL, D-dimer 3.49 mg/L, hemo-
globin 7.2 mg/dL, and platelet count 2000/mm3.
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An echocardiogram in March 2007 had demonstrat-
ed normal ejection fraction (> 55%); trivial aortic
regurgitation, tricuspid and mitral regurgitation; and
trivial pericardial effusion. Medications prior to ad-
mission included: hydrochlorothiazide 25 mg daily,
NPH and regular insulin, doxepin 25 mg at bedtime,
sertraline 100 mg daily, naproxen sodium as need-
ed for pain, oxycodone as needed for pain and vori-
nostat (Zolinza®) 400 mg daily.
On day one of hospitalization, the patient de-
veloped a pulseless polymorphic ventricular tachy-
cardia (shown in Fig. 3). A code was called during
which the patient spontaneously reverted to sinus
rhythm after brief cardiopulmonary resuscitation
(< 1 min) and without the need for defibrillation or
external pacing. Magnesium (2 g intravenously) was
given immediately. Potassium, which was 3.1 mmol/L
on morning laboratory assessment approximate-
ly 9.5 h prior to the episode of TdP, was also sup-
plemented. The patient was transferred to the car-
diac care unit (CCU) for overnight observation and
closer monitoring, and there was no recurrence of
torsade de pointes (TdP) during the remainder of
the hospitalization. Upon transfer to the CCU, dox-
epin and sertraline were discontinued. The patient’s
QTc interval initially decreased to 514 ms follow-
Figure 1. Admission electrocardiogram demonstrating QTc interval of 826 ms.
Figure 2. Electrocardiogram two years prior to current admission, demonstrating QTc interval of 400 ms.
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ing normalization of serum potassium to 4.9 mmol/L.
However, by day 4, the QTc interval remained
stable but prolonged at 559 ms. Serial cardiac mark-
ers (troponin T and creatine kinase-MB) were ne-
gative. An echocardiogram, obtained shortly after
arrival at the CCU, demonstrated enlargement of
the previously documented pericardial effusion with
respiratory flow variation, but there were no clini-
cal signs of tamponade. Left ventricular function
was unchanged from the previous echocardiogram.
Discussion
QT interval prolongation and
occurrence of torsade de pointes
It is known that acquired QT interval prolon-
gation, as in the case of drug-induced long QT syn-
drome, is associated with increased risk of TdP.
This is an important issue in patient care as this
rhythm is unstable and may degenerate to ventri-
cular fibrillation and subsequent sudden cardiac
death. The importance of this is exemplified by the
observation that QT interval prolongation and TdP
are among the commonest reasons for the restric-
tion of use or removal of prescription medications
from the United States market [1]. A number of
medications are known to prolong the QT interval,
including: antiarrhythmics, gastrointestinal promo-
tility agents, antimicrobials, antipsychotics, antide-
pressants, and other miscellaneous medications
such as methadone. In some cases, QTc interval
prolongation may be dose-dependent, while in oth-
ers, potassium channel blockage and subsequent
development of TdP may occur at any dosage [2].
However, it should be noted that most patients on
QT interval-prolonging medications never develop
TdP, and most patients with prolonged QT interval
do not progress to TdP.
Vorinostat and QT interval prolongation
Vorinostat is a targeted antineoplastic agent
approved by the United States Food and Drug Ad-
ministration (FDA) in October 2006 for the treat-
ment of cutaneous manifestations of CTCL in pa-
tients with progressive, persistent, or recurrent
disease on therapy or after trials of two systemic
therapies [3]. Vorinostat (suberoylanilide hydrox-
amic acid — SAHA) is a member of a class of his-
tone deacetylase inhibitors (HDAC), which specif-
ically inhibit the activity of the enzymes HDAC1,
HDAC2, HDAC3, and HDAC6. During phase I
study of intravenous SAHA, one patient experi-
enced an acute myocardial event and died; this was
later attributed to myocardial infarction unrelated
to study medication. This occurred during the one
week observation period following completion of
three weeks of SAHA (900 mg/m2) [4]. Reportedly,
ECGs demonstrated no changes from baseline and
no electrolyte abnormalities were noted. Nonethe-
less, an additional four patients were enrolled within
the same cohort to examine the cardiac effects of
the drug. ECGs performed before, during, and
Figure 3. Electrocardiogram demonstrating polymorphic ventricular tachycardia noted on telemetry when patient
was found to be pulseless.
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after treatment revealed only non-specific ST-seg-
ment changes. No cardiac dysrhythmias were re-
ported in this study. Subsequently, the oral prepa-
ration of SAHA was tested in a second phase I study.
A total of 73 patients were treated, each of whom
underwent baseline testing including ECG and fur-
ther cardiac workup as needed. Additionally, follow-
-up testing, including ECGs, were performed weekly
before each cycle of treatment (for a total of up to
eight weeks). Of the patients in this phase I trial,
34% developed mild to moderate dyspnea without
other cardiac symptoms or ECG findings. Serial
ECGs demonstrated non-specific ST-segment and
QT interval changes, which were not further de-
fined [5].
Patients in a phase II trial of oral vorinostat for
treatment of refractory CTCL underwent ECGs at
baseline and every three weeks while on study drug
for up to 67 weeks. Two participants died during
the study as a result of progression of disease and
sepsis, but there were no reported cases of sudden
cardiac death, clinically significant ECG changes, or
adverse cardiac events [6]. A phase IIb study of oral
vorinostat for treatment of progressive, recurrent,
or persistent stage IIB or higher mycosis fungoides/
/Sezary syndrome (MF/SS) found that the common-
est drug-related adverse experiences were gas-
trointestinal (diarrhea, nausea, dysgeusia, weight
loss, vomiting, constipation), constitutional (fatigue,
anorexia), and hematological. The most serious
adverse event occurring in more than one of the
74 patients was a thrombotic event. ECGs were per-
formed at baseline and after four weeks of therapy.
Electrocardiographic changes between baseline and
four weeks were noted in 15 patients, ten of whom
had documented cardiovascular disease at baseline
or documented baseline ECG abnormalities. Three
patients had QTc interval prolongation; one with
Grade 2 (> 470–500 ms or > 60 ms increase above
baseline) and two with Grade 1 (> 450–470 ms) QTc
interval prolongation. No cardiac symptoms were
noted; therefore, no vorinostat dosage modifications
or discontinuation were required [7]. In a retrospec-
tive analysis of the phase I and phase II studies,
116 patients had a baseline and at least one follow-
-up ECG. Four patients had Grade 2 (> 470–500 ms
or increase of > 60 ms above baseline) and one pa-
tient had Grade 3 (> 500 ms) QTc interval prolon-
gation. In 49 non-CTCL patients from three other
clinical trials in which complete evaluation of the
QT interval was performed, two had QTc intervals
of > 500 ms and one had QTc interval prolongation
of > 60 ms.
Other factors associated with
QT interval prolongation
In addition to vorinostat, the patient we present
was also receiving other drugs with the potential
to prolong the QT interval. Our patient was using
doxepin at low dose (25 mg at bedtime) for sleep.
One study of ECG effects of doxepin (mean daily
dosage at six weeks 169 ± 42 mg) and fluoxetine
in patients with major depression found that dox-
epin increased heart rate (69 ± 12 to 81 ± 13 bpm;
p = 0.0003) and prolonged the QTc interval (from
417 ± 36 to 439 ± 28 ms; p < 0.03) based on mea-
surements from signal-averaged ECGs. However,
no significant change in QRS or QTc durations were
noted with either drug on blinded review of 12-lead
ECG measurements [8]. In overdose, doxepin has
been associated with significant QT interval prolon-
gation and TdP, which responded well to treatment
with physostigmine [9, 10]. Our patient was also re-
ceiving sertraline 100 mg daily, which has been
shown to prolong the QT interval [11], and has been
associated with the development of TdP in overdose
[12]. It is unlikely that either doxepin or sertraline
at the doses used by our patient can account for the
marked QTc interval prolongation we observed.
Hypokalemia is a well known risk factor for
drug-induced long QT syndrome [13]. Paradoxical
reduction of the delayed rectifier K+ current may
occur with low extracellular potassium concentra-
tions via enhanced inactivation or enhanced com-
petitive block by sodium. Normalization of the QT
interval occurs following correction of potassium
levels to high-normal values. Our patient’s QTc
interval had decreased to 559 ms by day 4 of hospi-
talization following discontinuation of vorinostat,
doxepin and sertraline and normalization of serum
potassium.
Summary
Drug-induced QTc interval prolongation is as-
sociated with increased risk of the development of
TdP. In this case, an association was seen between
the administration of oral vorinostat and subsequent
QTc interval prolongation, which although greatly
improved over the course of hospitalization, persist-
ed despite correction of hypokalemia and discontin-
uation of other agents with the potential to prolong
the QTc interval. In addition, transient potential life-
threatening TdP was noted in our patient. At the
time this report was written, the patient had not
undergone a second trial of vorinostat therapy.
Therefore, the interaction is classified as possible
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based on the Naranjo ADR probability scale [14].
Thus, it seems reasonable to consider close moni-
toring for ECG changes, avoidance of other agents
with the potential to prolong the QT interval, and
careful electrolyte management among patients
receiving vorinostat therapy. It is expected that as
more insight is gained through continued use of
vorinostat, the association observed in this case
may be more accurately defined.
In conclusion, we report the first known case
of TdP in a patient treated with vorinostat with con-
comitant sertraline and doxepin therapy and mild
hypokalemia. These findings highlight the need for
periodic monitoring of electrolytes and ECGs in
patients receiving vorinostat, as recommended in
the prescribing information. An attempt should also
be made to avoid concurrent use of medications
known to prolong the QT interval in patients receiv-
ing vorinostat.
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